Nonalcoholic Steatohepatitis – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. With the launch of the first labeled / branded therapy on the horizon, we use claims data to examine how NASH is currently treated in the United States in both newly diagnosed and recently treated patients.
Questions answered
What patient shares do key off-label therapies and brands garner by line of therapy in newly diagnosed NASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NASH patients?
How have off-label therapies, including Intercept Pharmaceuticals’ Ocaliva, been integrated into the treatment algorithm, and what is their source of business?
What percentage of NASH patients receive off-label therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
What percentage of NASH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Nonalcoholic Steatohepatitis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
Treatment algorithms CDA nonalcoholic steatohepatitis US June 2022
Treatment algorithms CDA nonalcoholic steatohepatitis US 2022 dashboard
Sayani Datta, M.Sc.
Sayani Datta, M.Sc., is a principal analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Her primary area of focus is nonalcoholic steatohepatitis (NASH). She has worked on various types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She holds a master of science degree in biotechnology from the University of Leeds, where she gained exposure to life sciences research and development working as a postgraduate research intern.
Manasa Kadagathur, Ph.D.
Manasa Kadagathur, M.S. (Pharm.), Ph.D., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at Clarivate. She holds an M.S. (Pharm.) degree in medicinal chemistry from the National Institute of Pharmaceutical Education and Research (NIPER) in S.A.S. Nagar, India, and a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad, India. She earned her Ph.D. in medicinal chemistry from NIPER in Hyderabad, India.
